MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Date publication

avril 2016

Journal

Oncotarget

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry

Tous les auteurs :
Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26921265

Résumé

Addition of bevacizumab to trastuzumab-based neoadjuvant chemotherapy in HER2-positive inflammatory breast cancer (IBC) was associated with favorable outcome in the BEVERLY-2 phase II trial. Circulating levels of matrix metalloproteinases (MMP) 2 and 9 were correlated to high response rate and prolonged survival in high-grade glioma treated with bevacizumab. We examined the prognostic impact of MMP2 and MMP9 serum levels in BEVERLY-2 patients.

Mots clés

Adult, Aged, Angiogenesis Inhibitors, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Bevacizumab, administration & dosage, Chemotherapy, Adjuvant, Female, Humans, Inflammatory Breast Neoplasms, drug therapy, Matrix Metalloproteinase 2, blood, Matrix Metalloproteinase 9, blood, Middle Aged, Neoadjuvant Therapy, Treatment Outcome

Référence

Oncotarget. 2016 Apr;7(14):18531-40